437
Views
14
CrossRef citations to date
0
Altmetric
Review

Lorcaserin for weight management

, &
Pages 209-216 | Published online: 13 Jun 2013

References

  • Flegal KM Carroll MD Kit BK Ogden CL Prevalence of obesity and trends in the distribution of body mass index among US adults 1999–2010 JAMA 2012 307 491 497 22253363
  • Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 Atlanta, GA US Department of Health and Human Services, Centers for Disease Control and Prevention 2011 Available from: http://www.cdc.gov/diabetes/pubs/factsheet11.htm Accessed May 17, 2013
  • Boyle JP Thompson TJ Gregg EW Barker LE Williamson DE Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence Popul Health Metr 2010 8 29 20969750
  • Kramer H Cao G Dugas L Luke A Cooper R Durazio-Arvizu R Increasing BMI and waist circumference and prevalence of obesity among adults with type 2 diabetes: the National Health and Nutrition Examination Surveys J Diabetes Complications 2010 24 368 374 19914095
  • Eckel RH Kahn SE Ferrannini E Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab 2011 96 1654 1663 21602457
  • Inzucchi SE Nauck M Bergenstal RM American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 1364 1379 22517736
  • Ritter S Vetter ML Sarwer DB Lifestyle modifications and surgical options in the treatment of patients with obesity and type 2 diabetes mellitus Postgrad Med 2012 1244 168 180 22913905
  • Tuomilehto J Lindstrom J Eriksson JG Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 2001 344 1343 1350 11333990
  • Ilanne-Parikka P Eriksson JG Lindstrom J Finnish Diabetes Prevention Study Group Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study Diabetes Care 2008 31 805 807 18184907
  • Ilanne-Parikka P Laaksonen DE Eriksson JG Leisure-time physical activity and the metabolic syndrome in the Finnish Diabetes Prevention Study Diabetes Care 2010 33 1610 1617 20413514
  • Laaksonen DE Lindstrom J Tuomilehto J Uusitupa M Finnish Diabetes Prevention Study Group Increased physical activity as a cornerstone in the prevention of type 2 diabetes in high-risk individuals Diabetologia 2007 50 2607 2608 17724576
  • Wadden TA Butryn ML Wilson C Lifestyle modification for the management of obesity Gastroenterology 2007 132 2226 2238 17498514
  • Sarwer DB von Sydow Green A Vetter ML Wadden TA Behavorial therapy for obesity: where are we now? Curr Opin Endocrinol Diabetes Obes 2009 16 347 352 19623061
  • Perri MG Corsica JA Improving the maintenance of weight loss in behavioral treatment of obesity Wadden TA Stunkard AJ Handbook of Obesity Treatment 1st ed New York, NY Guilford Press 2002
  • Colman E Golden J Roberts M Egan A Weaver J Rosebraugh C The FDA’s assessment of two drugs for chronic weight management N Engl J Med 2012 367 1577 1579 23050510
  • Allison DB Gadde KM Garvey WT Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial Obesity 2011 20 330 342 22051941
  • Gadde KM Allison DB Ryan DH Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Lancet 2011 377 1341 1352 21481449
  • Garvey WT Ryan DH Look M Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo- controlled, phase 3 extension study Am J Clin Nutr 2012 95 297 308 22158731
  • US Food Drug Administration What is this new weight loss drug approved by the FDA? FDA Blogspot Available from: http://fdabelviq.blogspot.com/ Accessed May 17, 2013
  • Fidler MC Sanchez M Raether B A one-year randomized trial of lorcaserin for weight-loss in obese and overweight adults: the BLOSSOM trial J Clin Endocrinol Metab 2011 96 3067 3077 21795446
  • Smith SR Weissman NJ Anderson CM Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 2010 363 245 256 20647200
  • O’Neil PM Smith SR Weissman NJ Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study Obesity 2012 20 1426 1436 22421927
  • Belviq (lorcaserin hydrochloride) package insert Zofingen, Switzerland Arena Pharmaceuticals GmbH 2012
  • Flinn R Edney A Arena’s Diet Pill May Spur Renewed Race From Drugmakers Bloomberg Retrieved from: http://www.bloomberg.com/news/2012-2006-28/arena-s-diet-pill-may-spur-renewed-race-from-drugmakers.html Accessed May 17, 2013
  • Fabricatore AN Wadden TA Moore RH Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis Obes Rev 2009 10 333 341 19389060
  • Kolotkin RL Thomas D The Impact of Weight on Quality of Life-Lite (IWQOL-Lite) Office of Licensing and Ventures. Copyright 2013 Duke University Available from: http://www.qualityofifeconsulting.com/iwqol-lite.html Accessed April 10, 2013
  • Beck AT Steer RA Brown GK Beck Depression Inventory®–II Copyright © 2012 Pearson Education Inc. Available from: http://www.pearsonassessments.com/HAIWEB/Cultures/en-us/Productdetail.htm?Pid=015-8018-370 Accessed April 8, 2013
  • Schauer PR Kashyap SR Wolski K Bariatric surgery versus intensive medical therapy in obese patients with diabetes N Engl J Med 2012 366 1567 1576 22449319